Satellite SymposiumBeyond the revolution of MabThera
Andreas Engert
Do we have a new backbone in CLL?
Michael Hallek
Can we make MabThera better?
Andrew Davis
08:30 – 10:00
Room: Großer Saal
Scientific SessionBiology and Microenvironment
Margaret Shipp
Harald Stein
Microenvironment in Hodgkin Lymphoma
Randy Gascoyne
Molecular pathogenesis of Hodgkin Lymphoma
Martin Janz
Deregulation of di erentiation in pathogenesis of cHL
Thomas Wirth
Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma
Kimberley Jones
CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are
T-follicular helper cells
Ahmad Sattarzadeh
Analysis of myeloid suppressor marker Arginase identi es CD68+ / Arginase+ myeloid / monocytic subsets and exerts stronger prognostic in uence than macrophage quanti cation in Classical Hodgkin Lymphoma
Andrea Gallamini
10:30 – 12:00
Room: Großer Saal
Scientific SessionEarly Stages
Richard Hoppe
Aaron Polliack
Update on the NCRI RAPID trial
John Radford
An update on the EORTC / LYSA / FIL H10 trial
Marc André
WS report and further optimization in early stage Hodgkin Lymphoma
Andreas Engert
Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial
Karolin Behringer
De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes
Anita Kumar
Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial
Jeremy S. Abramson
12:15 – 13:45
Room: Großer Saal
Satellite SymposiumNHL and G-CSF – Focus on optimising the results
Helmut Ostermann
Introduction “Let’s get interactive”
Helmut Ostermann
Do we need G-CSF in Lymphoma Therapy?
Wolfgang Knauf
Norbert Schmitz
How much G-CSF is necessary in Lymphoma Therapy?
Hartmut Link
Current clinical Lymphoma trials based on G-CSF
Jens Hasskarl
Innovation and Best Practice – how to bene t
Helmut Ostermann
14:00 – 15:30
Room: Großer Saal
Scientific SessionHodgkin lymphoma in older patients
Magnus Björkholm
Andrew Lister
Epidemiology and biology
Magnus Björkholm
First line treatment
Stephen J. Proctor
Relapsed / refractory Hodgkin Lymphoma in older patients
Boris Böll
GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients
Boris Böll
Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma (HL): Preliminary toxicity ndings from a phase II window study
Andrew Evens
Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis
Aspasia Stamatoullas
15:45 – 17:30
Room: Großer Saal
Scientific SessionPET and prediction
Bertrand Coiffier
Andrea Gallamini
PET for early response prediction
Martin Hutchings
PET review in GHSG trials
Markus Dietlein
PETinrelapsedorrefractoryHodgkinLymphoma
Craig H. Moskowitz
Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US intergroup S0816
Oliver Press
Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)
Frank G. Keller
Tailored therapy in Hodgkin Lymphoma, based on prede ned risk factors and early interim PET / CT, Israeli H2 protocol: Preliminary report on 317 patients
Eldad J. Dann
17:45 – 19:15
Room: Großer Saal
Satellite SymposiumDefining Therapeutic Targets in T-Cell Lymphoma
Bertrand Coiffier
Welcome and Introduction
Bertrand Coiffier
Traditional Approaches to T-cell Lymphoma
Julie Vose
Q&A
Transition with targeted agents in T-cell Lymphoma
Bertrand Coiffier
Q&A
Targeting CD30 in T-cell Lymphoma
Tim Illidge
Q&A
Challenging the experts: An interactive panel discussion